A5014508405- Acute Ischemic Stroke Management
- Stroke Rehabilitation and Recovery
- Biomarkers in Disease Mechanisms
- Macrophage Migration Inhibitory Factor
- Galectins and Cancer Biology
- Traumatic Brain Injury and Neurovascular Disturbances
- Neurological Disease Mechanisms and Treatments
Huzhou Central Hospital
2023
Neurology, Inc
2021
<h3>Importance</h3> Preclinical and clinical studies have suggested a neuroprotective effect of remote ischemic conditioning (RIC), which involves repeated occlusion/release cycles on bilateral upper limb arteries; however, robust evidence in patients with stroke is lacking. <h3>Objective</h3> To assess the efficacy RIC for acute moderate stroke. <h3>Design, Setting, Participants</h3> This multicenter, open-label, blinded–end point, randomized trial including 1893 was conducted at 55...
Intravenous recombinant tissue plasminogen activator (r-tPA) and urokinase (UK) are both recommended for the treatment of acute ischaemic stroke (AIS) in China, but with few comparative outcome data being available. We aimed to compare outcomes these two thrombolytic agents patients within 4.5 hours onset AIS routine clinical practice China.A pre-planned, prospective, nationwide, multicentre, real-world registry consecutive (age ≥18 years) who received r-tPA or UK symptom according local...
Galectin-1 (Gal-1), a member of highly conserved family animal lectins, plays crucial role in controlling inflammation and neovascularization. However, the potential Gal-1 preventing myocarditis remains uncertain. We aimed to explore functions mechanisms myocarditis. In vivo, C57/BL6 mice were pre-treated with or without then exposed lipopolysaccharide (LPS) induce Subsequently, cardiac function, histopathology, inflammation, oxidative stress, apoptosis myocardial tissues detected. Following...